Suppressive effect of glucocorticoids on TNF-α production is associated with their clinical effect in multiple sclerosis

Abstract

A reduced sensitivity to glucocorticoids can affect the clinical effect of treatment with high-dose intravenous methylprednisolone in multiple sclerosis. We prospectively studied 27 multiple sclerosis patients who were treated with intravenous methylprednisolone. Before and after treatment in vitro stimulated TNF-α production in blood cells and the effect of in vitro administered glucocorticoids were determined as a measure of glucocorticoid sensitivity. The suppression of TNF-α production after intravenous methylprednisolone, and the in vitro suppressive effect of glucocorticoids prior to treatment was related to subsequent clinical improvement after intravenous methylprednisolone. The results suggest the existence of a partial glucocorticoid resistance, in a subgroup of multiple sclerosis patients, which may have implications for treatment efficacy.

Keywords

corticosteroids cytokines multiple sclerosis treatment response

Get full access to this article

View all access options for this article.

References

Filippini G. , Brusaferri F. , Sibley WA , et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; CD001331.

Van Winsen LM , Muris DF , Polman CH , Dijkstra CD , van den Berg TK , Uitdehaag BM Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab 2005; 90: 734-740.